Changing the regulations: Hope dies last. [NCA / SHAM]

posted by PharmCat  – Russia, 2021-10-01 20:48 (959 d 11:10 ago) – Posting: # 22613
Views: 2,653

❝ Hhm, can you elaborate?

these are my thoughts, I did not support them with any deep search ...
$$C = C_0 * e^{-k_e * t}$$ => $$C = \frac{D}{V_d} * e^{-k_e * t}$$
$$C = \frac{aX + \epsilon_2}{V_d} * e^{-bZ * t} * \epsilon_1 $$
$$ \epsilon_1 \sim N(0, \sigma_1^2); \epsilon_2 \sim N(0, \sigma_2^2)$$
It can be solved for \(a, V_d, b, \sigma_1^2, \sigma_2^2\) and modified for extravascular model.

Something described here: Korkmaz, Selcuk & Orman, Mehmet. (2012). The Use of Nonlinear Mixed Effects Models in Bioequivalence Studies: A Real Data Application. Open Access Scientific Reports. 1-11

However, I think terminal-phase adjusted area under the concentration curve method is something between the classic and NLME approaches. And both of them make corrections for variation from elimination.

Complete thread:

UA Flag
 Admin contact
23,029 posts in 4,834 threads, 1,641 registered users;
34 visitors (0 registered, 34 guests [including 8 identified bots]).
Forum time: 07:59 CEST (Europe/Vienna)

The most erroneous stories are those we think we know best–
and therefore never scrutinize or question.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz